Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis – Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P [ … ]

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis – Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P [ … ]

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome  – Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic – – In Addition to Post COVID Rea [ … ]

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September NEW YORK, August 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that t [ … ]

 Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President –  – Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceuti [ … ]

Immunic, Inc. to Announce Financial Results for the Second Quarter EndedJune 30, 2024, and Provide Corporate Update – Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK, August 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic infl [ … ]

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec  – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –  – Served as Neuroimmunology Franchise Head Responsible for Roche’s Blockbuster Launch of Multiple Scl [ … ]